

**EKF Diagnostics Holdings plc**  
("EKF" or the "Company")

**Share Buyback**

EKF Diagnostics Holdings plc(AIM: EKF), theAIM-listed global diagnostics business,announces that it has purchased a total of 141,000 of its ordinary shares of 1p each in the capital of the Company ("**Ordinary Shares**") at a weighted average price of 23.5 pence per share. The Ordinary Shares purchased will be held in treasury.

**Aggregated information**

|                                       |                  |
|---------------------------------------|------------------|
| Date of purchase                      | 15 December 2025 |
| Number of Ordinary Shares purchased   | 141,000          |
| Highest price paid per Ordinary Share | 23.5p            |
| Lowest price paid per Ordinary Share  | 23.5p            |
| Volume weighted average price paid    | 23.5p            |

**Transaction details**

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:

| Number of Ordinary Shares purchased | Transaction price (GBP) | Time of transaction | Trading venue |
|-------------------------------------|-------------------------|---------------------|---------------|
| 100,000                             | 23.5p                   | 15:14:31            | AIMX          |
| 41,000                              | 23.5p                   | 16:41:09            | AIMX          |

**Total voting rights**

Following the purchase, the Company's total issued share capital will consist of 435,383,092 Ordinary Shares, of which 141,000 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 435,242,092. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

**PDMR dealing**

As part of the buyback and within the above aggregate purchase, EKF acquired 41,000 Ordinary Shares in total at a price of 23.5 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited ("**Oryx**") and North Atlantic Smaller Companies Investment Trust PLC ("**NASCIT**"). EKF acquired 13,667 and 27,333 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.

Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 128,347,000 Ordinary Shares.

Additional disclosures relating to this PDMR dealing are detailed below.

*This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).*

*The person responsible for arranging the release of this Announcement on behalf of the Company is Julian Baines, Executive Chair.*

**EKF Diagnostics Holdings plc**  
Julian Baines, Executive Chair  
Gavin Jones, Chief Executive Officer

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
via Walbrook PR

**Tel: +44 (0)20 7496 3000**

**Singer Capital Markets (Nominated Adviser & Broker)**  
Phil Davies / Oliver Platts

**Walbrook PR Limited**  
Paul McManus / Alice Woodings

**Tel: +44 (0)20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)**  
**Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654**



**About EKF Diagnostics Holdings plc ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))**

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

|          |                                                                                                                                                                                                          |                                 |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| <b>1</b> | <b>Details of the person discharging managerial responsibilities / person closely associated</b>                                                                                                         |                                 |
| a)       | Name                                                                                                                                                                                                     | Christopher Mills               |
| <b>2</b> | <b>Reason for the notification</b>                                                                                                                                                                       |                                 |
| a)       | Position/status                                                                                                                                                                                          | Non-Executive Director          |
| b)       | Initial notification /Amendment                                                                                                                                                                          | Initial Notification            |
| <b>3</b> | <b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>                                                                                     |                                 |
| a)       | Name                                                                                                                                                                                                     | EKF Diagnostics Holdings plc    |
| b)       | LEI                                                                                                                                                                                                      | 213800DXTF3EAUK1AR05            |
| <b>4</b> | <b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b> |                                 |
| a)       | Description of the financial instrument, type of instrument                                                                                                                                              | Ordinary Shares of 1 pence each |

|          |                                                                  |                                                                                                   |  |          |           |       |        |
|----------|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|--|----------|-----------|-------|--------|
|          | Identification code                                              | GB0031509804                                                                                      |  |          |           |       |        |
| b)       | Nature of the transaction                                        | Disposal of Ordinary Shares                                                                       |  |          |           |       |        |
| c)       | Price(s) and volume(s)                                           | <table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>23.5p</td><td>41,000</td></tr></table> |  | Price(s) | Volume(s) | 23.5p | 41,000 |
| Price(s) | Volume(s)                                                        |                                                                                                   |  |          |           |       |        |
| 23.5p    | 41,000                                                           |                                                                                                   |  |          |           |       |        |
| d)       | Aggregated information<br><br>- Aggregated volume<br><br>- Price | n/a                                                                                               |  |          |           |       |        |
| e)       | Date of the transaction                                          | 15 December 2025                                                                                  |  |          |           |       |        |
| f)       | Place of the transaction                                         | London Stock Exchange, AIMX                                                                       |  |          |           |       |        |
|          |                                                                  |                                                                                                   |  |          |           |       |        |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSFFMFDMEISEIE